Get the app Watchlists Portfolios Alerts Sign in Get started

ABIVAX Société Anonyme ABVX

Full chart Compare

Set alert

89.49 USD +0.78 (+0.88%)

At closeNov 4, 2026, 7:51 PM EST

88.04 -1.45 -1.62%

After hours · Nov 4, 7:51 PM ET

87.79 Day range 90.87

72.50 52-week range 145.31

YTD: -33.64%
1 year: -9.28%

Discussion (3)

Tim F ABVX Jun 5, 2026 5 months ago #1

What a shit show that was. Beat the living hell outta it and then buy it back hand over fist…what?

Tim F ABVX Feb 3, 2026 9 months ago #2

Somebody wants this pharma company

Member ABVX Dec 11, 2025 10 months ago #3

Abvx/Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Terry Chrisomalis
Summary

Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis.
Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results.
Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
Recent $700M+ capital raise extends cash runway into Q4 2027, supporting ongoing pivotal trials and strategic expansion opportunitie